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Abstract: Individuals at risk (IAR) of familial pancreatic cancer (FPC) are good candidates for
screening. Unfortunately, neither reliable imaging modalities nor biomarkers are available to detect
high-grade precursor lesions or early cancer. Circulating levels of candidate biomarkers LCN2, TIMP1,
Glypican-1, RNU2-1f, and miRNA-196b were analyzed in 218 individuals with sporadic pancreatic
ductal adenocarcinoma (PDAC, n = 50), FPC (n = 20), chronic pancreatitis (n = 10), IAR with relevant
precursor lesions (n = 11) or non-relevant lesions (n = 5), 20 controls, and IAR with (n = 51) or
without (n = 51) lesions on pancreatic imaging. In addition, corresponding duodenal juice samples
were analyzed for Glypican-1 (n = 144) enrichment and KRAS mutations (n = 123). The panel
miR-196b/LCN2/TIMP1 could distinguish high-grade lesions and stage I PDAC from controls
with absolute specificity and sensitivity. In contrast, Glypican-1 enrichment in serum exosomes
and duodenal juice was not diagnostic. KRAS mutations in duodenal juice were detected in 9 of
12 patients with PDAC and only 4 of 9 IAR with relevant precursor lesions. IAR with lesions on
imaging had elevated miR-196b/LCN2/TIMP1 levels (p = 0.0007) and KRAS mutations in duodenal
juice (p = 0.0004) significantly more often than IAR without imaging lesions. The combination
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miR-196b/LCN2/TIMP1 might be a promising biomarker set for the detection of high-grade PDAC
precursor lesions in IAR of FPC families.
Keywords: pancreatic ductal adenocarcinoma; LCN2/NGAL; TIMP1; Glypican-1; miRNA-196b;
KRAS mutation
1. Introduction
Pancreatic ductal adenocarcinoma (PDAC) is a highly malignant tumor with a poor prognosis.
Familial pancreatic cancer (FPC) accounts for 3% to 5% of PDAC cases [1,2]. PDACs are characterized
by a progression from pancreatic intraepithelial neoplasia (PanIN) of low-grade over carcinoma in
situ (PanIN3) to invasive cancer. The majority of pancreatic specimens of resected FPC individuals
reveal multifocal PanINs in addition to small branch-duct intra-ductal papillary mucinous neoplasms
(BD-IPMN) [3,4]. In the setting of FPC imaging, BD-IPMNs might be surrogate markers for the presence
of high-grade PanIN lesions elsewhere in the gland [5]. Chronic pancreatitis (CP), which is a major
differential diagnosis of sporadic PDAC rarely occurs in patients with FPC [6,7]. In contrast, cystic
imaging lesions that are potentially BD-IPMNs are visualized in up to 53% of individuals at risk (IAR)
from FPC families [7,8].
A recent consensus stated that IAR for the development of PDAC should be screened for a
potential surgical treatment [6]. Members of FPC families with at least two affected first-degree
relatives are good candidates for screening [6,9]. Only the detection and surgical treatment of T1N0M0
adenocarcinoma and the high-grade precursor lesions PanIN3, main-duct (MD) IPMN, and BD-IPMN
with high-grade dysplasia are considered to be a true success of screening [6]. Since these lesions
are asymptomatic and very difficult to diagnose with current imaging procedures, there is a need
for biomarkers to facilitate screening of IAR in the setting of FPC. At present, there is a paucity of
biomarkers that detect early-stage PDAC. These should reliably identify those IAR with PanIN3
or IPMNs with high-grade dysplasia that would allow a potential curative resection. For routine
clinical use in FPC screening, biomarkers should consist of a small set that provides quick and
reproducible results.
In our previous studies with KPC mice and small patient series LCN2, TIMP1 and miR-196b were
identified as potential circulating markers for the early detection of PDAC and its high-grade precursor
lesions [10,11]. U2 snRNAs may also serve as novel diagnostic biomarkers for PDAC [12]. Glypican-1
enriched exosomes have been suggested to be reliable biomarkers for the detection of precursor lesions
and PDAC [13]. Mutations in KRAS were detected in pancreatic juice from 73% of PDAC patients [14].
These potential biomarkers were further evaluated and validated in a total of 218 individuals with
PDAC, FPC, CP, IAR with or without pathologically defined pancreatic lesions from FPC families and
healthy individuals.
2. Materials and Methods
2.1. Human Samples
Preoperative blood samples of patients with histologically proven PDAC, FPC, CP, and IAR who
underwent pancreatic resection for suspicious lesions were obtained from the prospective tissue bank
of the Department of Surgery, Philipps-University Marburg, and the FaPaCa registry. None of the IARs
nor the PDAC or CP patients who were resected had any preoperative treatment including neither
chemotherapy nor radiotherapy. When available, corresponding early post-operative (7–14 days after
resection) samples were also analyzed. Samples from 20 voluntary healthy individuals served as
controls. These were not analyzed in our previous pilot analyses [10,11] and constitute a validation
set for LCN2, TIMP1, and miR-196b. All tumors were histologically staged, according to UICC-TNM
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(Union for International Cancer Control; tumor, node, metastasis) classification 2017 [15]. Resection
specimens of IAR of FPC families who either underwent total pancreatectomy or partial pancreatic
resection were cut into 5 µm sections and screened for the presence of PanINs, IPMNs, and invasive
cancer by an experienced pathologist (G.K.). Multifocal PanIN1/2 and intra-ductal papillary mucinous
neoplasms (IPMN) with low-grade dysplasia were classified as potentially relevant lesions while only
PanIN3 lesions or IPMN with high-grade dysplasia were defined as significant lesions [7]. Serous
cystadenomas, multifocal PanIN1 lesions with focal centrolobular fibrosis, and IPMN with low or
medium grade dysplasia were considered to be non-relevant lesions. Serous cystadenomas, multifocal
PanIN1 lesions with focal centrolobular fibrosis, and IPMN with low or medium grade dysplasia were
considered to be non-significant lesions.
In addition, corresponding secretin-stimulated juice samples collected from the duodenum were
analyzed for Glypican-1 enriched exosomes (n = 144) and KRAS mutations (n = 123).
Blood and duodenal juice samples were analyzed from 102 IAR who participated in the
board-approved, prospective FaPaCa screening program [7,16] with endosonography every 1 to 3 years
including secretin-stimulated duodenal juice collection and annual magnetic resonance imaging with
magnetic resonance cholangiopancreatography (MRCP). The results were compared to the presence of
image-able pancreatic lesions. All subjects gave their informed written consent for inclusion before
they participated in the study. The study was conducted in accordance with the Declaration of Helsinki
and the protocol was approved by the Ethics Committee of the Philipps University Marburg, Germany
(No. 36/1997, amendment 5/2009).
2.2. RNA Isolation and Real-Time PCR MiR-196b
The PAXgene® system (Becton Dickinson, Bergen County, NJ, USA) was used to isolate total
RNA including miRNA from human samples using the PAXgene® system miRNA kit, according to
the manufacturer’s instructions. Real-time PCR was performed in triplicate. miR-196b was amplified
after specific reverse transcription using TaqMan MicroRNA assays and a TaqMan® MicroRNA
Reverse Transcription Kit (Applied Biosystems, Foster City, CA, USA), according to the manufacturer’s
instructions (Applied Biosystems). MiRNAs were normalized to miR-24, which is ubiquitously
expressed in normal and pancreatic tissues as previously described [17]. The relative expression was
determined by using the delta-delta Ct method and a >35 Ct value indicated negative amplification.
A ∆Ct value of 6.35 for miR-196b was calculated as a cutoff value that indicates the presence of
multifocal PanIN2/3 lesions or PDAC [11].
2.3. RNU2-1f
The serum levels of RNU2-1f were analyzed in 63 patients using RNA extraction, reverse
transcription, and real time PCR. The sera were spiked with 25 fmol of Caenorhabditis elegans
miRNA-54 (cel-miR-54) that served as a normalization control in real-time PCR, which was previously
described [12].
2.4. LCN2 and TIMP1
ELISAs of LCN2 and TIMP1 were performed in the preoperative and postoperative sera of
enrolled patients, as described previously [10]. Serum samples were diluted and tested for LCN2 and
TIMP1 in the corresponding human Quantikine ELISA Kits, DLCN20, and DTM100, respectively (R&D
Systems, Wiesbaden, Germany), according to the manufacturer’s instructions. ELISA plates were
read on an Emax precision microplate reader (Molecular Devices LLC, Sunnyvale, CA, USA) and the
data were analyzed using SoftMAX pro 6.4 software (Molecular Devices LLC). The calculated cutoff
values were 102 ng/mL for LCN2 and 273 ng/mL for TIMP1, according to our previously reported
analyses [10].
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2.5. CA 19-9
The serum marker, CA 19-9, was measured by using the electro-chemiluminescence
immunoassay (ECLIA), Elecsys®, from Roche Diagnostics Ltd. (Rotkreuz, Switzerland), according to
the manufacturer’s instructions.
2.6. Glypican-1 Circulating Exosomes (crExos) in Serum and Duodenal Juice
Extracellular vesicle (EV) isolation from human serum and duodenal juice samples was
performed, as previously described [13]. The samples were filtered through a 0.2 µm pore filter
and ultra-centrifuged at 150,000× g at 4 ◦C. This was completed overnight at first and then again for
2 h to obtain the EVs. Alternatively, EVs were isolated by using ExoQuick Solution, as suggested by the
manufacturer (System Biosciences, Palo Alto, CA, USA). EVs were attached to 4 mm aldehyde/sulfate
latex beads (Invitrogen, Carlsbad, CA, USA) by mixing 30 µg of vesicles with 10 µL volume of beads
in 100 µL PBS for 15 min at room temperature with a continuous rotation and then diluted to 1 mL
with PBS. The reaction was stopped with 100 mM glycine and 2% BSA in PBS. EV-bound beads were
washed, blocked with 10% BSA, and then incubated with anti-GPC1 (R&D Systems, 3 µL of antibody
in 20 µL of 2% solution of bovine serum albumin (BSA) for 30 min by rotating at 4 ◦C. The beads
were centrifuged for 1 min at 14,800× g, the supernatant was discarded, and the beads were washed
in 2% BSA. Alexa-488-tagged secondary antibodies (Abcam, 3 µL of antibody in 20 µL of 2% BSA)
were used for 30 min with a rotation at 4 ◦C. SECONDARY antibody incubation alone was used as
a control and to gate the beads with GPC1-bound vesicles. The percentage of positive beads was
calculated relative to the total number of beads analyzed per sample (100,000 events). This percentage
was referred to as the percentage of beads with GPC1 vesicles. The isolated EVs were characterized by
using the ZetaView-Particle-Tracking-Analyzer and found to have the appropriate size for exosomes.
In addition, the exosomal proteins CD9 (Merck, Darmstadt, Germany), Flotillin-1 (Abcam, Cambridge,
UK), and Glypican-1 (R&D Systems, Wiesbaden, Germany) were detected on Western blots.
2.7. KRAS Mutation Analysis of Duodenal Juice
Pancreatic juice secretion was stimulated by infusing synthetic secretin (Secrulux®, Sanochemia
Diagnostic, Neuss, Germany) and was then collected from the duodenal lumen. Circulating DNA was
isolated by using the QIAamp® Circulating Nucleic Acid Kit (Qiagen, Hilden, Germany) and was
tested for the presence of mutant KRAS by using the therascreen® KRAS Pyro® Kit (Qiagen), according
to the manufacturer’s instructions.
2.8. Statistical Analysis
For analyses of miR-196b, LCN2, TIMP1, RNU2-1f, Glypican-1, and CA 19-9 levels in human
samples, the Wilcoxon signed rank test as well as the logistic regression modeling was applied.
The resulting predicted values were analyzed again by the calculation of a ROC (Receiver Operating
Characteristic) curve and the determination of sensitivity, specificity, and AUC (Area Under Curve).
The steps were conducted with R version 2.13.1 in addition to PRISM 6 for Mac OS X from GraphPad
Software, Inc. (San Diego, CA, USA). A value of p < 0.05 was considered significant.
3. Results
A summary of the clinical characteristics of 96 patients resected for pancreatic disease and 20
normal controls is presented in Table 1. Subjects with PDAC were significantly older (median 67.5,
range 40 to 84 years) than the IAR groups (median 58 and 60 years, p < 0.0322). There was no significant
difference between groups regarding body-mass-index (BMI), the presence of diabetes, smoking, or a
history of pancreatitis.
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Table 1. Patients’ characteristics.
Parameter SporadicPDAC FPC CP
Healthy
Controls
IAR Relevant
Lesions #
IAR Non-Relevant
Lesions
n 50 20 10 20 11 5
Gender,
male/female 27/23 7/13 5/5 11/9 2/9 2/3
Age, years,
median (range) 67.5 (40 to 84) 63.5 (47 to 82) 52.5 (44 to 75) 47 (21 to 71) 58 (47 to 77) 60 (42 to 61)
BMI, mean ± SD 26.8 ± 4.3 22.2 ± 3.2 24.1 ± 4.6 23.6 ± 1.9 25.1 ± 2.9 27.4 ± 5.1
Smoking history 20/50 (40%) 6/20 (30%) 2/10 (20%) 5/20 (25%) 3/11 (27%) 0/5 (0%)
Pancreatitis 6/50 (12%) 0/20 (0%) 10/10 (100%) 0/20 (0%) 1/11 (9%) 0/5 (0%)
Diabetes 12/50 (24%) 4/20 (20%) 5/10 (50%) 1/20 (5%) 1/11 (9%) 0/5 (0%)
#, relevant lesions include multifocal PanIN2/3 lesions and IPMN with high grade dysplasia, non-relevant
lesions include serous cystadenoma and multifocal PanIN 1 lesions with focal fibrosis, PDAC, pancreatic
ductal adenocarcinoma, FPC, familial pancreatic cancer, CP, chronic pancreatitis, IAR, individual at risk, BMI,
body-mass-index, SD, standard deviation.
3.1. Serum Analysis of Resected Patients
In the first step, the expression of biomarkers miR-196b, LCN2, TIMP1, RNU2-1f, and CA 19-9
was analyzed in 116 serum samples of patients or IAR who underwent pancreatic resections for PDAC
(n = 50, 5 stage I, 38 stage II and 7 stage III), FPC (n = 20, 6 stage II, 1 stage III and 13 stage IV),
CP (n = 10), significant lesions (n = 5), potentially relevant lesions (n = 6), non-relevant lesions such as
multifocal PanIN1 or serous cystadenoma (n = 5), and healthy controls (n = 20), respectively. CA 19-9
was elevated in 85% of patients with PDAC, 100% of FPC patients, 40% of CP patients, but in none
of the IAR with or without relevant precursor lesions nor in normal controls. RNU2-1f performed
best in discriminating between PDAC and healthy controls as well as between PDAC and CP, but it
failed to distinguish between potentially relevant or significant precursor lesions from healthy controls
(Tables 2 and 3). In contrast, the serum levels of Glypican-1 enriched crExos could not distinguish
between patients with PDAC or IAR with significant precursor lesions and healthy controls or IAR
without significant lesions (Tables 2 and 3) since 7 of 10 analyzed healthy individuals revealed elevated
levels of Glypican-1 crExos.
Table 2. Biomarker results of patients with pathologically defined lesions.
Elevated Biomarker PDAC *(n = 50)
FPC
(n = 20)
CP
(n = 10)
PDAC ** Stage I
(n = 5)
IAR-RL #
(n = 11)
IAR-NRL #
(n = 5)
Controls
(n = 20)
miR-196b 50/50 20/20 4/10 5/5 10/11 0/5 0/20
LCN2 42/50 20/20 2/10 5/5 7/10 0/5 0/20
TIMP1 49/50 20/20 3/10 5/5 7/10 0/5 0/20
Glypican-1 25/29 15/20 7/10 2/2 7/9 2/5 7/10
RNU2-1f 15/15 10/10 0/21 n.a. 0/7 n.a. 0/10
CA 19-9 39/46 14/14 4/10 3/5 0/11 0/5 0/3
miR-196b + LCN2 + TIMP1 41/50 20/20 0/10 5/5 7/10 0/5 0/20
KRAS in duodenal juice 9/12 n.a. n.a. 1/1 4/9 n.a. 0/10
Glypican-1 in duodenal juice 9/9 n.a. n.a. 2/2 6/6 n.a. 5/5
*, PDACs include 5 stage I, 38 stage II, and 7 stage III tumors that were potentially curative resected. FPCs include 1
stage IIA, 5 stage IIB, 1 stage III, and 13 stage IV tumors, **, These 5 stage I PDACs are included in the total of 50
PDACs, #, relevant lesions (RL) include potentially relevant, PDAC, pancreatic ductal adenocarcinoma, IAR-RL,
individual at risk-relevant lesions, n.a., not available.
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Table 3. Performance of serum biomarkers in a combined validation set.
Comparison Marker p AUC (95% CI) Sensitivity at 95%Specificity
Specificity at 95%
Sensitivity
PDAC vs. Healthy control
miR-196b 0.0051 0.8938(0.7395 to 1.048) 80% 50%
TIMP1 <0.0001 0.9617(0.9125 to 1.011) 93.6% 70%
LCN2 0.0007 0.9500(0.8477 to 1.052) 50% 90%
RNU2-1f <0.0001 1.0000(1.0000 to 1.000) 100% 100%
Glypican-1 0.2700
0.6106
(0.4332 to
0.7881)
31% 0%
FPC vs. Healthy control
miR-196b 0.0006 0.9716(0.9052 to 1.038) 90% 70%
TIMP1 0.0001 0.9600(0.8871 to 1.033) 86% 50%
LCN2 <0.0001 0.9786(0.9289 to 1.028) 78% 90%
RNU2-1f 0.0002 1.0000(1.0000 to 1.000) 100% 100%
Relevant lesions vs. Healthy
controls
miR-196b 0.0011 0.9722(0.9034 to 1.041) 88.9% 75%
TIMP1 0.0048 0.9600(0.8633 to 1.057) 80% 80%
LCN2 0.0024 0.9667(0.8857 to 1.048) 67% 90%
RNU2-1f 0.8073
0.537
(0.2468 to
0.8247)
14.3% 10%
Glypican-1 0.9717
0.5046
(0.2438 to
0.7655)
11.1% 16.7%
Significant lesions vs. Healthy
controls miR-196b 0.0066
1.0000
(1.0000 to 1.000) 100% 100%
High grade only
TIMP1 0.0047 1.0000(1.0000 to 1.000) 100% 100%
LCN2 0.0047 1.0000(1.0000 to 1.000) 100% 100%
RNU2-1f 0.3580
0.6625
(0.3679 to
0.9571)
25% 50%
PDAC vs. chronic pancreatitis
miR-196b 0.0539 0.7550(0.5074 to 1.003) 60% 70%
TIMP1 0.0126 0.8300(0.6132 to 1.047) 10% 80%
LCN2 0.0015 0.920(0.7673 to 1.073) 20% 90%
RNU2-1f <0.0001 1.0000(1.0000 to 1.000) 100% 100%
Glypican-1 0.9615
0.5052
(0.2850 to
0.7213)
10.3% 0%
FPC vs. chronic pancreatitis
miR-196b 0.0411 0.7636(0.5475 to 0.979) 55% 0%
TIMP1 0.0078 0.8200(0.6232 to 1.017) 21% 60%
LCN2 0.0004 0.9286(0.8029 to 1.054) 36% 80%
RNU2-1f <0.0001 1.0000(1.0000 to 1.000) 100% 100%
PDAC, pancreatic ductal adenocarcinoma, FPC, familial pancreatic cancer, AUC, area under curve, CI,
confidence interval.
The blood levels of miR-196b were elevated in all patients with PDAC, FPC, and in 10 of 11 IAR
with potentially relevant or significant precursor lesions compared to normal expression in healthy
individuals and IAR with non-relevant precursor lesions (Tables 2 and 3). Thus, all patients with
stage I PDACs (n = 5) and all 5 significant lesions and 5 of 6 potentially relevant precursor lesions
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showed elevation of miR-196b levels. LCN2 and TIMP1 were also present at normal levels in healthy
individuals and IAR with non-relevant lesions but were elevated in 84% and 98% of PDAC cases
including all 5 stage I PDAC cases and 70% (7 of 10) each of IAR cases with significant and potentially
relevant lesions (Table 2). None of these markers alone could discriminate among all groups with
high accuracy. However, the marker panel miR-196b, TIMP1, and LCN2 could distinguish significant
lesions and stage I PDAC from healthy individuals with an AUC, sensitivity, and specificity of 1 each
and a predictive value of 100% (Table 4, Figure 1).
Table 4. Performance of the serum biomarker panel miR-196b + TIMP1 + LCN2.
Comparison p AUC (95% CI) Sensitivity at 95%Specificity
Specificity at 95%
Sensitivity
PDAC vs. Healthy control 0.0012 0.93 (0.8162 to 1.044) 80% 80%
FPC vs. Healthy control 0.0004 0.97 (0.9071 to 1.033) 80% 80%
Significant lesions and stage I
PDAC vs. healthy controls 0.029 1 (1.000 to 1.000) 100% 100%
PDAC vs. chronic pancreatitis 0.0025 0.9 (0.7559 to 1.044) 50% 80%
FPC vs. chronic pancreatitis 0.0007 0.95 (0.8622 to 1.038) 80% 80%
PDAC, pancreatic ductal adenocarcinoma, FPC, familial pancreatic cancer, AUC, area under curve, CI,
confidence interval.
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Figure 1. MRCP (magnetic resonance cholangiopancreatography) (A) and MRI (magnetic resonance 
imaging) (B) of a 77-year-old female individual at risk (IAR) with a cystic dilated Wirsung duct, a 
potentially main-duct intra-ductal papillary mucinous neoplasia (IPMN) from a familial pancreatic 
cancer (FPC) family with four affected relatives. The IAR underwent total pancreatectomy and 
pathological examination revealed a main duct IPMN with multifocal moderate and severe dysplasia. 
Preoperative serum levels of miR-196b, LCN2, and TIMP1 were strongly elevated and dropped to 
normal levels at postoperative day 10. Arrows indicate the cystic dilated Wirsung duct. 
It is of note that postoperative circulating levels of all three markers dropped to normal levels in 
22 patients from whom corresponding postoperative serum samples were available (five stage I 
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Figure 1. MRCP (magnetic resonance cholangiopancreatography) (A) and MRI (magnetic resonance
imaging) (B) of a 77-year-old female individual at risk (IAR) with a cystic dilated Wirsung duct,
a potentially main-duct intra-ductal papillary mucinous neoplasia (IPMN) from a familial pancreatic
cancer (FPC) fa ily with four affected relatives. The IAR underwent total pancreatecto y and
pathological exa ination revealed a ain duct IP ith ultifocal oderate and severe dysplasia.
Preoperative seru levels of iR-196b, LC 2, and TI P1 ere strongly elevated and dropped to
nor al levels at postoperative day 10. rro s indicate the cystic dilated irsung duct.
i f note that postoperative circulating levels of all three markers dropped to normal l vels
in 22 patients from whom corresponding postoperative serum samples were available (five sta e
PDAC, five significant, and five potentially relevant precursor lesions, Table 5). Details of biomarker
analyses of IAR who underwent pancreatic resections for suspicious lesions are shown in Table 5.
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Table 5. Detailed biomarker results in IAR with histologically defined pancreatic lesions (n = 16)
compared to stage I PDAC and controls.
IAR with
Histologically
Verified
Lesions
Pre-OP
KRAS
Mutation in
Duodenal
Juice
Pre-OP
Elevated
miR-196b
Pre-OP
Elevated
LCN2
Pre-OP
Elevated
TIMP1
Pre-OP
Elevated
miR-196b
+ LCN2
Pre-OP
Elevated
miR-196b
+
TIMP1
Pre-OP
Elevated
LCN2 +
TIMP1
Pre-OP
Elevated
miR-196b +
LCN2 +
TIMP1
Post-OP not
Elevated
miR-196b,
TIMP1,
LCN2 *
Sporadic stage
I PDAC (n = 5) 1/1 5/5 5/5 5/5 5/5 5/5 5/5 5/5 5/5
PanIN3 (n = 3) 1/3 3/3 3/3 3/3 3/3 3/3 3/3 3/3 3/3
IPMN with
HGD (n = 2) 1/1 2/2 2/2 2/2 2/2 2/2 2/2 2/2 2/2
Multifocal
PanIN2 or
IPMN with
MGD (n = 6)
2/5 5/6 2/5 2/5 2/5 2/5 2/5 2/5 5/5
PanIN 1 or
focal fibrosis
(n = 2)
n.a. 0/2 0/2 0/2 0/2 0/2 0/2 0/2 n.a.
Serous
cystadenoma
(n = 3)
n.a. 0/3 0/3 0/3 0/3 0/3 0/3 0/3 n.a.
Normal
controls
(n = 20)
0/10 0/20 0/20 0/20 0/20 0/20 0/20 0/20 n.a.
PanIN, pancreatic intraepithelial neoplasia, IPMN, intraductal papillary mucinous neoplasia, MGD, moderate
grade dysplasia, HGD, high grade dysplasia, n.a., not available, *, only potentially curative resected patients with
pre-operative and postoperative serum samples, IAR, individual at risk, PDAC, pancreatic ductal adenocarcinoma,
OP, operation.
3.2. Duodenal Juice Analysis of Resected Patients
KRAS mutations in secretin stimulated duodenal juice were detected in 75% (9/12) of PDAC
patients and 44% (4/9) of IAR with either significant (n = 2) or potentially relevant (n = 2) precursor
lesions (Tables 2 and 5) but not in healthy individuals (0/10). Among these 13 patients, distinct KRAS
mutations were detected in the following frequencies: G12V, 9 of 13 (69.3%), G12D, 2 of 13 (15.3%),
G12S, 1 of 13 (7.6%), and G12C, 1 of 13 (7.6%). Overall, KRAS mutations had only a modest sensitivity
to detect potentially relevant or significant precursor lesions. As in serum, the levels of Glypican-1
crExos could not discriminate between PDAC, IAR with significant or potentially relevant lesions,
and normal controls in duodenal juice samples (Table 2). The analysis of miR-196b, TIMP1, and LCN2
in duodenal juice samples was not possible or gave non-reproducible results.
3.3. Biomarker Analysis of IAR with or without Pancreatic Imaging Lesions
IAR who had not undergone surgery included 51 IAR without pancreatic lesions and 51 IAR
with pancreatic lesions on imaging. In 47 of 51 (92%) IAR with lesions, at least one cystic lesion was
detected measuring between 3 and 14 mm and in 4 (8%) IAR indeterminable lesions of <10 mm were
detected. The median follow-up from first imaging to the most recent screening visit was 30 (range of 1
to 64) months. Characteristics and biomarker analyses of IARs are presented in Table 6. There were no
differences in gender, BMI, presence of diabetes, or the history of pancreatitis between the two groups.
IAR with imaging lesions were significantly older (median 52 vs. 46 years, p = 0.006) than IAR without
imaging lesions while almost twice as many IAR without imaging lesions had a history of smoking
(32% vs. 19%, p = 0.157).
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Table 6. Characteristics and biomarker analysis of IAR with or without imaging lesions who did not
undergo surgery.
Parameter
IAR with
Imaging Lesions
(n = 51)
IAR without
Imaging Lesions
(n = 51)
Controls
(n = 20)
p-Value
IAR with Lesions vs.
IAR without Lesions
Gender (male/female) 23/28 22/29 11/9 p = 1.0
Age, years, median (range) 52 (30 to 74) 46 (27 to 63) 47 (21 to 71) p = 0.0006
BMI, mean ± SD 25.8 ± 3.6 25.0 ± 4.3 23.6 ± 1.9 p = 1.0
Smoking history 19% (9/47) 32% (14/43) 25% (5/20) p = 0.157
Diabetes 4.2% (2/48) 4.3% (2/46) 5% (1/20) p = 1.0
History of pancreatitis 4.2% (2/48) 4.3% (2/46) 0% (0/20) p = 1.0
miR-196b elevated * 46/51 (90%) 10/51 (20%) 0/20 p < 0.0001
LCN2 elevated * 34/51 (67%) 17/51 (33%) 0/20 p = 0.0014
TIMP1 elevated * 19/51 (37%) 14/51 (27%) 0/20 p = 0.397
crExosGlypican-1 enriched * 29/51 (57%) 26/50 (52%) 7/10 (70%) p = 0.691
CA 19-9 elevated * 2/51 (3.9%) 1/51 (2%) 0/3 NS
miR-196b + LCN2 + TIMP1 elevated * 19/51 (37%) 4/51 (8%) 0/20 p = 0.0007
KRAS mutated in duodenal juice 27/51 (53%) 9/51 (17%) 0/20 p = 0.0004
crExos Glypican-1 enriched in duodenal juice 20/20 (100%) 15/17 (88%) 3/3 p = 0.204
KRAS mutated in duodenal juice +
miR196b/LCN2/TIMP1 elevated 8/51 (16%) 0/51 (0%) 0/20 p = 0.0058
*, as determined in blood, bold, statistically significant, mut., mutation, IAR, individual at risk, BMI,
body-mass-index, NS, not significant.
According to the cutoff values determined in our previous studies [10,11], miRNA-196b and
LCN2 were elevated in 90% (46/51) and 67% (34/51) of IAR with imaging lesions compared to
only 20% (10/51) and 33% (17/51) of IAR without imaging lesions (p < 0.05), respectively (Table 6).
The elevation of these biomarkers was not dependent on age. In contrast, the elevation of TIMP1 levels
was not significantly different between the groups (37%, 19/51 vs. 27%, 14/51). Overall, IAR with
pancreatic lesions on imaging (n = 51) had an elevated marker set miR-196b/LCN2/TIMP1 (19/51,
37%) significantly more often than IAR without imaging lesions (4/51, 8%, p = 0.0007). As already
stated above, none of the healthy controls revealed elevation of any of the markers. CA 19-9 was
elevated in only 3.9% (2/51) of IAR with and in 2% (1/51) of IAR without pancreatic imaging lesions.
Glypican-1 crExos were enriched in serum from 57% (29/51) of IAR with lesions and 52% (26/50)
of IAR without lesions and in 7 of 10 controls tested (Table 6). Levels of Glypican-1 crExos from
duodenal juice were also elevated in almost all IAR analyzed as well as in healthy controls (Table 6).
In addition, 53% (27/51) of IAR with imaging lesions revealed KRAS mutations in the duodenal
juice compared to only 17% (9/51) of IAR without imaging lesions (p = 0.0004) and none of the healthy
controls. The most frequently detected KRAS mutation was G12V (n = 32, 89%), which was followed
by G12C (n = 2, 5.5%) and G12S (n = 2, 5.5%). The presence of a KRAS mutation was not dependent
on age in either IAR group. Eight of 51 (16%) of IAR with imaging lesions revealed KRAS mutations
and elevation of the three markers miRNA-196b, TIMP1, and LCN2 compared to 0 of 51 (0%) of IAR
without imaging lesions (Table 6).
4. Discussion
There has been a growing effort to study circulating biomarkers in PDAC with the aim of
identifying noninvasive, reproducible, and cost-effective diagnostic biomarkers that can aid in early
diagnosis of PDAC. Biomarkers that reliably indicate the presence of PanIN and IPMN lesions with
high-grade dysplasia or early PDAC (T1) allow curative resection, which would be of great value for
screening IAR from FPC families. This is especially true in light of a recent review that shows that
screening of IAR from FPC families resulted in preventive or curative surgery in only 2.5% (25 of 988)
of patients if one considers the resection of histologically confirmed high-grade precursors and stage I
PDAC [18].
The only biomarker available for PDAC to date is CA 19-9. However, its sensitivity for PDAC
and, more importantly, for potentially relevant or significant (e.g., PanIN2 and PanIN 3, respectively)
precursor lesions is poor. Therefore, its use as a diagnostic biomarker is not recommended [19]. In the
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present study, only three of five stage I PDAC and 0 of 11 IAR with potentially relevant or significant
precursor lesions had elevated CA 19-9 levels.
Several potential biomarkers for the diagnosis of PDAC have been reported, but rarely for its
precursor lesions especially in the setting of FPC [4,13,14,20,21]. Thus, the present study focused on
biomarkers that might enable the detection of PanINs and IPMNs with advanced dysplasia as well as
early PDAC (stage I) in the setting of FPC. The biomarker set miR-196b/LCN2/TIMP1 distinguished
IAR with significant precursor lesions and stage I PDAC from healthy controls with absolute specificity
and sensitivity. However, this biomarker set had a limited sensitivity and specificity of 80% each for
the discrimination between CP and multifocal PanIN2/3. This reduced sensitivity is negligible in
the setting of FPC because individuals with FPC rarely have chronic inflammation of the gland [6,7].
The good performance of the combination of miR-196b, LCN2, and TIMP1 as a potential biomarker
panel for the detection of early disease in IAR of FPC families is not surprising. TIMP1 has been
proposed to be a potential diagnostic biomarker for PDAC [10,22–25]. The Alliance of Pancreatic
Cancer Consortia for Biomarkers for Early Detection recently stated that, while no biomarker is ready
for a validation trial, TIMP1 had sufficiently high sensitivity and specificity to warrant additional
research especially in combination with other biomarkers to form a panel [21]. The biomarker panel
TIMP1/leucine-rich alpha 2-glycoprotein 1/ CA 19-9 significantly improves the detection of early-stage
PDAC [24]. However, patients with precursor lesions were not analyzed in that study. TIMP1 is also
part of the CancerSEEK [25].
MiR-196b has previously been shown to be the most selectively and differentially expressed
miRNA in micro-dissected PanIN3 lesions [26] and it was the most up-regulated miRNA in 248
PDAC tissues including stage I when compared to normal pancreatic duct cells on an miRNA array
analysis [27]. Furthermore, the two-miRNA index “miR-196b-miR-217” was suggested to be a useful
tool for distinguishing patients with PDAC from those with a normal pancreas and CP based on a
validation in 241 paraffin-embedded pancreato-bilary cancers and 74 benign pancreas tissues [28].
In our former pilot study on transgenic KPC animals and a small patient series, we showed that the
combination of miRNAs 196a and 196b reached a sensitivity of 1 and specificity of 0.9 (area under the
curve = 0.99) to diagnose PDAC or its high-grade precursor lesions [11].
Transcripts of LCN2 were significantly higher in the majority of solid tumors including PDAC
when compared to normal tissues [29]. A recent review stated that the discriminative power of
LCN2 between PDAC patients and controls was acceptable, but the diagnostic accuracy remained
uncertain [30]. LCN2 discriminated between PDAC and CP [24,29,31] with limited accuracy and was
eliminated from validation tests by some groups [24,30]. However, in the setting of FPC, CP plays
only a minor role as a differential diagnosis. More importantly, LCN2 expression was detected in the
PanIN-stage [31] and it could differentiate between mucinous pancreatic cysts and non-mucinous
cysts [32], which suggests that it could be a marker of premalignant changes in the pancreas. Given
that TIMP1 and LCN2 may be elevated in other cancer types [29], they are best suited as part of a panel
for subjects at increased risk such as those with a history of FPC.
A recent study on 190 patients with PDAC indicated a strong correlation between Glypican-1
crExos and PDAC [13]. We cannot confirm this observation. Glypican-1 crExos were not diagnostic for
PDAC or its relevant precursor lesions in the present cohort. Our results are supported by Lai et al. [33]
who demonstrated that Glypican-1 crExos were not significantly different between normal controls
and pre-resection PDAC samples.
The present analysis is clearly limited by the small number of stage I PDAC and high grade
precursor serum samples as in all previous series and, thus, cannot define any biomarker panel for
the screening of IAR from FPC families with enough statistical power. However, these samples are
extremely rare. According to a recent review on resection results of published, board-approved FPC
screening programs, only 2.5% (25 of 988) of IAR revealed high-grade precursor lesions (n = 23) or
stage I PDAC (n = 2) [18]. In the future, these rare samples from board-approved programs should be
combined for the evaluation and validation of biomarkers in the setting of FPC screening.
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With the present work, only three studies describe molecular analyses on blood and duodenal
juice samples of IAR from FPC families undergoing regular screening [14,34]. We demonstrate in this
paper that the biomarker panel miR-196b/LCN2/TIMP1 was elevated in IAR with pancreatic lesions
significantly more often than in IAR without imaging lesions and normal controls (Table 6). In addition,
IAR with imaging lesions revealed KRAS mutations in secretin-stimulated duodenal juice more often
than IAR without imaging lesions (p = 0.0004). This partially supports the results of a previous study
on secretin-stimulated duodenal juice samples of 194 IAR from FPC families [14]. These authors
also detected KRAS mutations significantly more often in IAR undergoing cancer screening than in
controls. Next generation sequencing was performed on pancreatic juice samples from IAR undergoing
surveillance and patients with PDAC [34]. Mutation concentrations could distinguish patients with
PDAC or high-grade dysplasia from other subjects. These studies provide important information
but are only descriptive. The only way to prove the diagnostic accuracy of any marker panel such as
miR-196b/LCN2/TIMP1 would be to resect the pancreas with a subsequent pathological examination.
However, this is not yet ethically justified. Further annual long-term follow-up will determine whether
IAR with elevated levels of miR-196b/LCN2/TIMP1 with or without the presence of KRAS mutations
in duodenal juice will develop significant precursor lesions or PDAC. This is vital since it has been
estimated that 15 to 20 years may lapse before early PanIN or IPMN lesions might be indicated by our
biomarker set to become PDAC [35,36].
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